Publications

Nathan Bahary

Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019 Mar 2; doi: 10.1053/j.gastro.2019.02.037. PubMed PMID: 30836094.
Yepuri N, Bahary N, Jain A, Dhir M. Review and Update on the Role of Peritoneal Cytology in the Treatment of Gastric Cancer. J Surg Res. 2019 Mar;235607-614. doi: 10.1016/j.jss.2018.10.049. PubMed PMID: 30691849.
Sun W, Patel A, Normolle D, Patel K, Ohr J, Lee JJ, Bahary N, Chu E, Streeter N, Drummond S. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer. 2019 Mar 15;125(6):902-909. doi: 10.1002/cncr.31872. PubMed PMID: 30561756; PMCID: PMC6402964.
McGovern JM, Singhi AD, Borhani AA, Furlan A, McGrath KM, Zeh HJ 3rd, Bahary N, Dasyam AK. CT Radiogenomic Characterization of the Alternative Lengthening of Telomeres Phenotype in Pancreatic Neuroendocrine Tumors. AJR Am J Roentgenol. 2018 Nov;211(5):1020-1025. doi: 10.2214/AJR.17.19490. PubMed PMID: 30160983.
Brand R, Borazanci E, Speare V, Dudley B, Karloski E, Peters MLB, Stobie L, Bahary N, Zeh H, Zureikat A, Hogg M, Lee K, Tsung A, Rhee J, Ohr J, Sun W, Lee J, Moser AJ, DeLeonardis K, Krejdovsky J, Dalton E, LaDuca H, Dolinsky J, Colvin A, Lim C, Black MH, Tung N. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Cancer. 2018 Sep 1;124(17):3520-3527. doi: 10.1002/cncr.31628. PubMed PMID: 30067863.
Thakur PC, Miller-Ocuin JL, Nguyen K, Matsuda R, Singhi AD, Zeh HJ, Bahary N. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. J Transl Med. 2018 Jul 9;16(1):190. doi: 10.1186/s12967-018-1562-z. PubMed PMID: 29986726; PMCID: PMC6038181.
Chao DT, Shah NH, Zeh HJ 3rd, Singhi AD, Bahary N, McGrath KM, Fasanella KE, Zureikat AH, Whitcomb DC, Brand RE. Overweight or Obese Individuals at Eighteen Years of Age Develop Pancreatic Adenocarcinoma at a Significantly Earlier Age. Gastroenterol Res Pract. 2018;20182380596. doi: 10.1155/2018/2380596. PubMed PMID: 29967636; PMCID: PMC6008748.
Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, Zeh HJ 3rd, Hogg ME. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time. Ann Surg Oncol. 2018 Nov;25(12):3483-3491. doi: 10.1245/s10434-018-6521-7. PubMed PMID: 29786131.
Dhir M, Zenati MS, Hamad A, Singhi AD, Bahary N, Hogg ME, Zeh HJ 3rd, Zureikat AH. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. Ann Surg Oncol. 2018 Jul;25(7):1896-1903. doi: 10.1245/s10434-018-6512-8. PubMed PMID: 29761331.
Sutera P, Bernard ME, Wang H, Bahary N, Burton S, Zeh H, Heron DE. Stereotactic Body Radiation Therapy for Locally Progressive and Recurrent Pancreatic Cancer after Prior Radiation. Front Oncol. 2018;852. doi: 10.3389/fonc.2018.00052. PubMed PMID: 29564223; PMCID: PMC5845878.
El-Khoueiry AB, O'Donnell R, Semrad TJ, Mack P, Blanchard S, Bahary N, Jiang Y, Yen Y, Wright J, Chen H, Lenz HJ, Gandara DR. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2018 May;81(5):957-963. doi: 10.1007/s00280-018-3553-4. PubMed PMID: 29520435; PMCID: PMC6330274.
Roy S, LaFramboise WA, Liu TC, Cao D, Luvison A, Miller C, Lyons MA, O'Sullivan RJ, Zureikat AH, Hogg ME, Tsung A, Lee KK, Bahary N, Brand RE, Chennat JS, Fasanella KE, McGrath K, Nikiforova MN, Papachristou GI, Slivka A, Zeh HJ, Singhi AD. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times. Gastroenterology. 2018 Jun;154(8):2060-2063.e8. doi: 10.1053/j.gastro.2018.02.026. PubMed PMID: 29486199; PMCID: PMC5985217.
Dudley B, Karloski E, Monzon FA, Singhi AD, Lincoln SE, Bahary N, Brand RE. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy. Cancer. 2018 Apr 15;124(8):1691-1700. doi: 10.1002/cncr.31242. PubMed PMID: 29360161.
Davar D, Bahary N. Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. Target Oncol. 2018 Apr;13(2):125-140. doi: 10.1007/s11523-017-0547-9. PubMed PMID: 29302770.
Quan K, Sutera P, Xu K, Bernard ME, Burton SA, Wegner RE, Zeh H, Bahary N, Stoller R, Heron DE. Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma. Pract Radiat Oncol. 2018 Mar - Apr;8(2):95-106. doi: 10.1016/j.prro.2017.10.001. PubMed PMID: 29291966.
Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J Clin Oncol. 2018 Feb 1;36(4):359-366. doi: 10.1200/JCO.2017.74.9564. PubMed PMID: 29232172.
Boone BA, Zeh HJ 3rd, Bahary N. Autophagy Inhibition in Pancreatic Adenocarcinoma. Clin Colorectal Cancer. 2018 Mar;17(1):25-31. doi: 10.1016/j.clcc.2017.10.013. PubMed PMID: 29223362.
Sutera PA, Bernard ME, Gill BS, Harper KK, Quan K, Bahary N, Burton SA, Zeh H, Heron DE. One- vs. Three-Fraction Pancreatic Stereotactic Body Radiation Therapy for Pancreatic Carcinoma: Single Institution Retrospective Review. Front Oncol. 2017;7272. doi: 10.3389/fonc.2017.00272. PubMed PMID: 29184848; PMCID: PMC5694485.
Dhir M, Zenati MS, Jones HL, Bartlett DL, Choudry MHA, Pingpank JF, Holtzman MP, Bahary N, Hogg ME, Zeh HJ 3rd, Geller DA, Wallis Marsh J, Tsung A, Zureikat AH. Effectiveness of Hepatic Artery Infusion (HAI) Versus Selective Internal Radiation Therapy (Y90) for Pretreated Isolated Unresectable Colorectal Liver Metastases (IU-CRCLM). Ann Surg Oncol. 2018 Feb;25(2):550-557. doi: 10.1245/s10434-017-6265-9. PubMed PMID: 29181682.
Dhir M, Malhotra GK, Sohal DPS, Hein NA, Smith LM, O'Reilly EM, Bahary N, Are C. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol. 2017 Oct 10;15(1):183. doi: 10.1186/s12957-017-1240-2. PubMed PMID: 29017581; PMCID: PMC5634869.
Ocuin LM, Miller-Ocuin JL, Zenati MS, Vargo JA, Singhi AD, Burton SA, Bahary N, Hogg ME, Zeh HJ 3rd, Zureikat AH. A margin distance analysis of the impact of adjuvant chemoradiation on survival after pancreatoduodenectomy for pancreatic adenocarcinoma. J Gastrointest Oncol. 2017 Aug;8(4):696-704. doi: 10.21037/jgo.2017.04.02. PubMed PMID: 28890820; PMCID: PMC5582038.
Hamad A, Singhi AD, Bahary N, McGrath K, Amarin R, Zeh HJ, Zureikat AH. Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer. J Natl Compr Canc Netw. 2017 Aug;15(8):983-988. doi: 10.6004/jnccn.2017.0140. PubMed PMID: 28784859.
Schenker Y, Bahary N, Claxton R, Childers J, Chu E, Kavalieratos D, King L, Lembersky B, Tiver G, Arnold RM. A Pilot Trial of Early Specialty Palliative Care for Patients with Advanced Pancreatic Cancer: Challenges Encountered and Lessons Learned. J Palliat Med. 2018 Jan;21(1):28-36. doi: 10.1089/jpm.2017.0113. PubMed PMID: 28772092; PMCID: PMC5757080.
Nguyen KT, Kalyan A, Beasley HS, Singhi AD, Sun W, Zeh HJ, Normolle D, Bahary N. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response. J Gastrointest Oncol. 2017 Jun;8(3):556-565. doi: 10.21037/jgo.2017.01.23. PubMed PMID: 28736642; PMCID: PMC5506273.
Epelboym I, Zenati MS, Hamad A, Steve J, Lee KK, Bahary N, Hogg ME, Zeh HJ, Zureikat AH. Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival. Ann Surg Oncol. 2017 Sep;24(9):2744-2751. doi: 10.1245/s10434-017-5975-3. PubMed PMID: 28681155.
Singhi AD, Ali SM, Lacy J, Hendifar A, Nguyen K, Koo J, Chung JH, Greenbowe J, Ross JS, Nikiforova MN, Zeh HJ, Sarkaria IS, Dasyam A, Bahary N. Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma. J Natl Compr Canc Netw. 2017 May;15(5):555-562. PubMed PMID: 28476735.
Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study. Oncotarget. 2017 May 23;8(21):35326-35338. doi: 10.18632/oncotarget.15108. PubMed PMID: 28186961; PMCID: PMC5471058.
Dhir M, Choudry HA, Holtzman MP, Pingpank JF, Ahrendt SA, Zureikat AH, Hogg ME, Bartlett DL, Zeh HJ, Singhi AD, Bahary N. Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies. Cancer Med. 2017 Jan;6(1):195-206. doi: 10.1002/cam4.992. PubMed PMID: 28028924; PMCID: PMC5269696.
Dhir M, Ramalingam L, Shuai Y, Pakrafter S, Jones HL, Hogg ME, Zureikat AH, Holtzman MP, Ahrendt SA, Bahary N, Pingpank JF, Zeh HJ, Bartlett DL, Choudry HA. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion in Adolescent and Young Adults with Peritoneal Metastases. Ann Surg Oncol. 2017 Apr;24(4):875-883. doi: 10.1245/s10434-016-5689-y. PubMed PMID: 27995449.
Bednar F, Zenati MS, Steve J, Winters S, Ocuin LM, Bahary N, Hogg ME, Zeh HJ 3rd, Zureikat AH. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? Ann Surg Oncol. 2017 May;24(5):1406-1413. doi: 10.1245/s10434-016-5707-0. PubMed PMID: 27896518.
Wright GP, Poruk KE, Zenati MS, Steve J, Bahary N, Hogg ME, Zuriekat AH, Wolfgang CL, Zeh HJ 3rd, Weiss MJ. Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis. J Gastrointest Surg. 2016 Nov;20(11):1830-1835. doi: 10.1007/s11605-016-3256-2. PubMed PMID: 27604886.
Dhir M, Jones HL, Shuai Y, Clifford AK, Perkins S, Steve J, Hogg ME, Choudry MH, Pingpank JF, Holtzman MP, Zeh HJ 3rd, Bahary N, Bartlett DL, Zureikat AH. Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study. Ann Surg Oncol. 2017 Jan;24(1):150-158. doi: 10.1245/s10434-016-5418-6. PubMed PMID: 27431415.
Singhi AD, Liu TC, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, Tsung A, Marsh JW, Lee KK, Hogg ME, Bahary N, Brand RE, McGrath KM, Slivka A, Cressman KL, Fuhrer K, O'Sullivan RJ. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. Clin Cancer Res. 2017 Jan 15;23(2):600-609. doi: 10.1158/1078-0432.CCR-16-1113. PubMed PMID: 27407094.
Olevian DC, Nikiforova MN, Chiosea S, Sun W, Bahary N, Kuan SF, Pai RK. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival. Hum Pathol. 2016 Mar;49124-34. doi: 10.1016/j.humpath.2015.11.004. PubMed PMID: 26826419.
Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20;33(36):4284-92. doi: 10.1200/JCO.2015.62.8719. PubMed PMID: 26527777; PMCID: PMC4678179.
Singhi AD, Krasinskas AM, Choudry HA, Bartlett DL, Pingpank JF, Zeh HJ, Luvison A, Fuhrer K, Bahary N, Seethala RR, Dacic S. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol. 2016 Jan;29(1):14-24. doi: 10.1038/modpathol.2015.121. PubMed PMID: 26493618.
Chao DT, Shah NH, Zeh HJ 3rd, Bahary N, Whitcomb DC, Brand RE. Increased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus. Pancreas. 2016 Feb;45(2):228-33. doi: 10.1097/MPA.0000000000000439. PubMed PMID: 26418902; PMCID: PMC4710546.
Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst. 2015 Nov;107(11): doi: 10.1093/jnci/djv248. PubMed PMID: 26374429; PMCID: PMC4849360.
Mas-Moya J, Dudley B, Brand RE, Thull D, Bahary N, Nikiforova MN, Pai RK. Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-like syndrome versus patients with Lynch syndrome. Hum Pathol. 2015 Nov;46(11):1616-25. doi: 10.1016/j.humpath.2015.06.022. PubMed PMID: 26319271.
Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee FC, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O'Reilly EM, Goldenberg DM, Von Hoff DD. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. Eur J Cancer. 2015 Sep;51(14):1857-64. doi: 10.1016/j.ejca.2015.06.119. PubMed PMID: 26187510.
Boone BA, Bahary N, Zureikat AH, Moser AJ, Normolle DP, Wu WC, Singhi AD, Bao P, Bartlett DL, Liotta LA, Espina V, Loughran P, Lotze MT, Zeh HJ 3rd. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Ann Surg Oncol. 2015 Dec;22(13):4402-10. doi: 10.1245/s10434-015-4566-4. PubMed PMID: 25905586; PMCID: PMC4663459.
Shakir M, Tang D, Zeh HJ, Tang SW, Anderson CJ, Bahary N, Lotze MT. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow. Pancreas. 2015 May;44(4):528-34. doi: 10.1097/MPA.0000000000000298. PubMed PMID: 25872129.
Dudley B, Brand RE, Thull D, Bahary N, Nikiforova MN, Pai RK. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression. Am J Surg Pathol. 2015 Aug;39(8):1114-20. doi: 10.1097/PAS.0000000000000425. PubMed PMID: 25871621.
Singhi AD, Foxwell TJ, Nason K, Cressman KL, McGrath KM, Sun W, Bahary N, Zeh HJ, Levy RM, Luketich JD, Davison JM. Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival. Am J Surg Pathol. 2015 Apr;39(4):487-95. doi: 10.1097/PAS.0000000000000356. PubMed PMID: 25634752; PMCID: PMC4374440.

<< Investigators Search

Top